Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows from Operating Activities:
Net income (loss)	$ 50,758	$ 70,795
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation expense, intangible asset and other amortization	40,190	31,896
Stock-based compensation	16,119	13,543
Equity in earnings of equity method investments	(2,244)	(2,127)
Distributions from equity method investments	3,672	3,492
Change in fair value of contingent consideration	(3,998)	(3,014)
Deferred taxes, net	2,328	3,434
Changes in operating assets and liabilities:
Sales (purchases) of investments, net	23,843	3,834
Accounts receivable, net and other assets	5,877	9,460
Accrued compensation and benefits, accounts payable, accrued liabilities and other liabilities	(90,787)	(103,610)
Operating activities of consolidated investment products ("CIP"):
Net cash provided by (used in) operating activities	93,325	71,970
Cash Flows from Investing Activities:
Capital expenditures	(3,695)	(4,534)
Acquisition of business, net of cash acquired of $2.7 million	(196,110)	0
Net cash provided by (used in) investing activities	(199,805)	(4,012)
Cash Flows from Financing Activities:
Borrowings on credit agreement	50,000	0
Repayments on credit agreement	(22,000)	(1,375)
Common stock dividends paid	(34,156)	(32,967)
Repurchase of common shares	(20,467)	(50,000)
Payment of contingent consideration	(21,861)	(23,140)
Taxes paid related to net share settlement of restricted stock units	(5,523)	(6,965)
Investment management subsidiary equity sales (purchases)	0	(1,053)
Net contributions from (distributions to) noncontrolling interests	(227)	15,300
Financing activities of CIP:
Net cash provided by (used in) financing activities	(84,428)	(226,525)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(340)	1,594
Net increase (decrease) in cash, cash equivalents and restricted cash	(191,248)	(156,973)
Cash, cash equivalents and restricted cash, beginning of period	478,186	400,309
Cash, cash equivalents and restricted cash, end of period	286,938	243,336
Non-Cash Investing and Financing Activities:
Contingent consideration	109,420	0
Common stock dividends payable	15,894	15,183
Reconciliation of cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at end of period	286,938	243,336
Consolidated Entity excluding Consolidated Investment Products
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Realized and unrealized (gains) losses on investments of CIP, net	(5,326)	(2,987)
Operating activities of consolidated investment products ("CIP"):
Realized and unrealized (gains) losses on investments of CIP, net	(5,326)	(2,987)
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	176,229
Consolidated Investment Products
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Realized and unrealized (gains) losses on investments of CIP, net	(2,907)	6,903
Operating activities of consolidated investment products ("CIP"):
Realized and unrealized (gains) losses on investments of CIP, net	(2,907)	6,903
Purchases of investments by CIP	(677,371)	(538,448)
Sales of investments by CIP	740,428	581,278
Net proceeds (purchases) of short-term investments and securities sold short by CIP	3	(120)
Change in other assets and liabilities of CIP	(7,260)	(2,359)
Cash Flows from Investing Activities:
Change in cash and cash equivalents of CIP due to consolidation (deconsolidation), net	0	522
Financing activities of CIP:
Payments on borrowings by CIP	(399,440)	(126,325)
Borrowings by CIP	369,246	0
Non-Cash Investing and Financing Activities:
Increase (decrease) to noncontrolling interests due to consolidation (deconsolidation) of CIP, net	0	$ (166)
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	109,621
Cash pledged or on deposit of CIP	$ 1,088